Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 252

1.

Systemic autoimmune diseases and the kidney.

Rovin BH.

Kidney Int. 2020 Feb;97(2):222-225. doi: 10.1016/j.kint.2019.11.002. No abstract available.

PMID:
31980066
2.

Do kidneys grow old gracefully?

Rovin BH.

Kidney Int. 2020 Jan;97(1):40-41. doi: 10.1016/j.kint.2019.08.031. No abstract available.

PMID:
31901356
3.

Implementing the Kidney Health Initiative Surrogate Efficacy Endpoint in Patients With IgA Nephropathy (the PROTECT Trial).

Barratt J, Rovin B, Diva U, Mercer A, Komers R; PROTECT Study Design Group.

Kidney Int Rep. 2019 Aug 19;4(11):1633-1637. doi: 10.1016/j.ekir.2019.08.007. eCollection 2019 Nov. No abstract available.

4.

Kidney International celebrates the 60th anniversary of the International Society of Nephrology.

Ronco P, Rovin B, Nangaku M, Jha V.

Kidney Int. 2019 Dec;96(6):1248-1249. doi: 10.1016/j.kint.2019.10.001. No abstract available.

PMID:
31759479
5.

The Kidney Biopsy in Systemic Lupus Erythematosus: A View of the Past and a Vision of the Future.

Ayoub I, Cassol C, Almaani S, Rovin B, Parikh SV.

Adv Chronic Kidney Dis. 2019 Sep;26(5):360-368. doi: 10.1053/j.ackd.2019.08.015. Review.

PMID:
31733720
6.

Kidney biopsy-based management of maintenance immunosuppression is safe and may ameliorate flare rate in lupus nephritis.

Malvar A, Alberton V, Lococo B, Ferrari M, Delgado P, Nagaraja HN, Rovin BH.

Kidney Int. 2020 Jan;97(1):156-162. doi: 10.1016/j.kint.2019.07.018. Epub 2019 Aug 20.

PMID:
31685314
7.

Development of a Set of Lupus-Specific Ambulatory Care Sensitive, Potentially Preventable Adverse Conditions: A Delphi Consensus Study.

Feldman CH, Speyer C, Ashby R, Bermas B, Bhattacharyya S, Chakravarty E, Everett B, Ferucci E, Hersh AO, Marty FM, Merola JF, Ramsey-Goldman R, Rovin BH, Son MB, Tarter L, Waikar S, Yazdany J, Weissman JS, Costenbader KH.

Arthritis Care Res (Hoboken). 2019 Oct 18. doi: 10.1002/acr.24095. [Epub ahead of print]

PMID:
31628721
8.

Rethinking Lupus Nephritis Classification on a Molecular Level.

Almaani S, Prokopec SD, Zhang J, Yu L, Avila-Casado C, Wither J, Scholey JW, Alberton V, Malvar A, Parikh SV, Boutros PC, Rovin BH, Reich HN.

J Clin Med. 2019 Sep 23;8(10). pii: E1524. doi: 10.3390/jcm8101524.

9.

Role of ANA testing in the classification of patients with systemic lupus erythematosus.

Pisetsky DS, Spencer DM, Rovin B, Lipsky PE.

Ann Rheum Dis. 2019 Sep 20. pii: annrheumdis-2019-216259. doi: 10.1136/annrheumdis-2019-216259. [Epub ahead of print] No abstract available.

PMID:
31540932
10.

Anti-PD-1 Immunotherapy May Induce Interstitial Nephritis With Increased Tubular Epithelial Expression of PD-L1.

Cassol C, Satoskar A, Lozanski G, Rovin B, Hebert L, Nadasdy T, Brodsky SV.

Kidney Int Rep. 2019 Jun 20;4(8):1152-1160. doi: 10.1016/j.ekir.2019.06.001. eCollection 2019 Aug.

11.

Global consensus building and prioritisation of fundamental lupus challenges: the ALPHA project.

Manzi S, Raymond S, Tse K, Peña Y, Anderson A, Arntsen K, Bae SC, Bruce I, Dörner T, Getz K, Hanrahan L, Kao A, Morand E, Rovin B, Schanberg LE, Von Feldt JM, Werth VP, Costenbader K.

Lupus Sci Med. 2019 Jul 19;6(1):e000342. doi: 10.1136/lupus-2019-000342. eCollection 2019.

12.

Immunostaining for galactose-deficient immunoglobulin A is not specific for primary immunoglobulin A nephropathy.

Cassol CA, Bott C, Nadasdy GM, Alberton V, Malvar A, Nagaraja HN, Nadasdy T, Rovin BH, Satoskar AA.

Nephrol Dial Transplant. 2019 Aug 1. pii: gfz152. doi: 10.1093/ndt/gfz152. [Epub ahead of print]

PMID:
31369128
13.

Successful Treatment and Five Years of Disease-free Survival in a Donor Transmitted Metastatic Melanoma with Ipilimumab Therapy.

Singh P, Pandey D, Rovin B, Pesavento TE, Olencki T.

Cureus. 2019 May 14;11(5):e4658. doi: 10.7759/cureus.4658.

14.

Rituximab or Cyclosporine in the Treatment of Membranous Nephropathy.

Fervenza FC, Appel GB, Barbour SJ, Rovin BH, Lafayette RA, Aslam N, Jefferson JA, Gipson PE, Rizk DV, Sedor JR, Simon JF, McCarthy ET, Brenchley P, Sethi S, Avila-Casado C, Beanlands H, Lieske JC, Philibert D, Li T, Thomas LF, Green DF, Juncos LA, Beara-Lasic L, Blumenthal SS, Sussman AN, Erickson SB, Hladunewich M, Canetta PA, Hebert LA, Leung N, Radhakrishnan J, Reich HN, Parikh SV, Gipson DS, Lee DK, da Costa BR, Jüni P, Cattran DC; MENTOR Investigators.

N Engl J Med. 2019 Jul 4;381(1):36-46. doi: 10.1056/NEJMoa1814427.

PMID:
31269364
15.

Standardized Outcomes in Nephrology-Glomerular Disease (SONG-GD): establishing a core outcome set for trials in patients with glomerular disease.

Carter SA, Lightstone L, Cattran D, Bagga A, Barbour SJ, Barratt J, Boletis J, Caster D, Coppo R, Fervenza FC, Floege J, Hladunewich M, Hogan JJ, Kitching AR, Lafayette R, Malvar A, Radhakrishnan J, Rovin BH, Zhang H, Gutman T, Howell M, Logeman C, Shen JI, Teixeira-Pinto A, Alexander SI, Cho Y, Craig JC, Harris D, Johnson DW, Kerr PG, Ryan J, Viecelli AK, Wang AY, Wilkie M, Scholes-Robertson N, Tong A; SONG-GD Initiative.

Kidney Int. 2019 Jun;95(6):1280-1283. doi: 10.1016/j.kint.2019.01.047. No abstract available.

PMID:
31122702
16.

Outcome of participants with nephrotic syndrome in combined clinical trials of lupus nephritis.

Gomez Mendez LM, Cascino MD, Katsumoto TR, Brakeman P, Brunetta P, Jayne D, Dall'Era M, Rovin B, Garg J.

Lupus Sci Med. 2019 Feb 4;6(1):e000308. doi: 10.1136/lupus-2018-000308. eCollection 2019.

17.

Response to 'Antinuclear antibodies by indirect immunofluorescence and solid phase assays' by Bossuyt et al.

Pisetsky DS, Spencer DM, Lipsky PE, Rovin BH.

Ann Rheum Dis. 2019 May 10. pii: annrheumdis-2019-215479. doi: 10.1136/annrheumdis-2019-215479. [Epub ahead of print] No abstract available.

PMID:
31076389
18.

The authors reply.

Rovin BH, Solomons N, Huizinga RB.

Kidney Int. 2019 Apr;95(4):992-993. doi: 10.1016/j.kint.2018.12.010. No abstract available.

PMID:
30904071
19.

Commentary on the Current Guidelines for the Diagnosis of Lupus Nephritis Flare.

Ayoub I, Birmingham D, Rovin B, Hebert L.

Curr Rheumatol Rep. 2019 Feb 27;21(4):12. doi: 10.1007/s11926-019-0809-x. Review.

PMID:
30810824
20.

Citius, altius, fortius . . . . faster, higher, stronger.

Ronco P, Rovin B; Associate Editors; Entire Editorial Team.

Kidney Int. 2019 Mar;95(3):476-478. doi: 10.1016/j.kint.2019.01.001. No abstract available.

PMID:
30784651
21.

Lupus nephritis is linked to disease-activity associated expansions and immunity to a gut commensal.

Azzouz D, Omarbekova A, Heguy A, Schwudke D, Gisch N, Rovin BH, Caricchio R, Buyon JP, Alekseyenko AV, Silverman GJ.

Ann Rheum Dis. 2019 Jul;78(7):947-956. doi: 10.1136/annrheumdis-2018-214856. Epub 2019 Feb 19.

22.

Management and treatment of glomerular diseases (part 2): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.

Rovin BH, Caster DJ, Cattran DC, Gibson KL, Hogan JJ, Moeller MJ, Roccatello D, Cheung M, Wheeler DC, Winkelmayer WC, Floege J; Conference Participants.

Kidney Int. 2019 Feb;95(2):281-295. doi: 10.1016/j.kint.2018.11.008.

23.

Management and treatment of glomerular diseases (part 1): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.

Floege J, Barbour SJ, Cattran DC, Hogan JJ, Nachman PH, Tang SCW, Wetzels JFM, Cheung M, Wheeler DC, Winkelmayer WC, Rovin BH; Conference Participants.

Kidney Int. 2019 Feb;95(2):268-280. doi: 10.1016/j.kint.2018.10.018.

PMID:
30665568
24.

Reimagining the kidney biopsy in the era of diagnostic biomarkers of glomerular disease.

Rovin BH, Almaani S, Malvar A.

Kidney Int. 2019 Feb;95(2):265-267. doi: 10.1016/j.kint.2018.11.016.

PMID:
30665567
25.

Response to: 'Can solid-phase assays replace immunofluorescence for ANA screening?' by Bizzaro.

Pisetsky DS, Spencer DM, Lipsky PE, Rovin BH.

Ann Rheum Dis. 2020 Mar;79(3):e33. doi: 10.1136/annrheumdis-2018-214829. Epub 2019 Jan 18. No abstract available.

PMID:
30659048
26.

Response to: "Antinuclear autoantibodies: discordance among four different assays" by Pacheco et al.

Pisetsky DS, Spencer DM, Lipsky PE, Rovin B.

Ann Rheum Dis. 2020 Jan;79(1):e7. doi: 10.1136/annrheumdis-2018-214766. Epub 2018 Dec 1. No abstract available.

PMID:
30504443
27.

Response to: 'ANA testing in "real life"' by Infantino et al.

Pisetsky DS, Spencer DM, Lipsky PE, Rovin BH.

Ann Rheum Dis. 2020 Jan;79(1):e4. doi: 10.1136/annrheumdis-2018-214650. Epub 2018 Nov 17. No abstract available.

PMID:
30448767
28.

A randomized, controlled double-blind study comparing the efficacy and safety of dose-ranging voclosporin with placebo in achieving remission in patients with active lupus nephritis.

Rovin BH, Solomons N, Pendergraft WF 3rd, Dooley MA, Tumlin J, Romero-Diaz J, Lysenko L, Navarra SV, Huizinga RB; AURA-LV Study Group.

Kidney Int. 2019 Jan;95(1):219-231. doi: 10.1016/j.kint.2018.08.025. Epub 2018 Nov 9.

PMID:
30420324
29.

Zonal cortical scarring and tubular thyroidization in kidney biopsies of patients with SLE-histologic indicator for antiphospholipid antibodies.

Shah R, Brodsky SV, Hebert L, Rovin BH, Nadasdy T, Satoskar AA.

Lupus. 2018 Dec;27(14):2236-2244. doi: 10.1177/0961203318809177. Epub 2018 Nov 7.

PMID:
30403144
30.

Preserved Renal Allograft Function and Successful Treatment of Metastatic Merkel Cell Cancer Post Nivolumab Therapy.

Singh P, Visger Von J, Prosek J, Rovin B, Pesavento TE, Olencki T, Pandey D.

Transplantation. 2019 Feb;103(2):e52-e53. doi: 10.1097/TP.0000000000002502. No abstract available.

PMID:
30365468
31.

Advances and Challenges on New Therapies and Clinical Targets of Acute Kidney Injury.

Kang R, Rovin B.

Toxicol Pathol. 2018 Dec;46(8):925-929. doi: 10.1177/0192623318800688. Epub 2018 Oct 3. Review.

PMID:
30278835
32.

Establishing Surrogate Kidney End Points for Lupus Nephritis Clinical Trials: Development and Validation of a Novel Approach to Predict Future Kidney Outcomes.

Mackay M, Dall'Era M, Fishbein J, Kalunian K, Lesser M, Sanchez-Guerrero J, Levy DM, Silverman E, Petri M, Arriens C, Lewis EJ, Korbet SM, Conti F, Tesar V, Hruskova Z, Borba EF, Bonfa E, Chan TM, Rathi M, Gupta KL, Jha V, Hasni S, West MR, Solomons N, Houssiau FA, Romero-Diaz J, Mejia-Vilet J, Rovin BH.

Arthritis Rheumatol. 2019 Mar;71(3):411-419. doi: 10.1002/art.40724. Epub 2019 Feb 1.

PMID:
30225865
33.

Limited Reliability of the Spot Urine Protein/Creatinine Ratio in the Longitudinal Evaluation of Patients With Lupus Nephritis.

Shidham G, Ayoub I, Birmingham D, Hebert P, Rovin B, Diamond B, Wofsy D, Hebert L.

Kidney Int Rep. 2018 Apr 27;3(5):1057-1063. doi: 10.1016/j.ekir.2018.04.010. eCollection 2018 Sep.

34.

B-cell therapy in lupus nephritis: an overview.

Almaani S, Rovin BH.

Nephrol Dial Transplant. 2019 Jan 1;34(1):22-29. doi: 10.1093/ndt/gfy267. Review.

35.

Urine inositol pentakisphosphate 2-kinase and changes in kidney structure in early diabetic kidney disease in type 1 diabetes.

Looker HC, Merchant ML, Rane MJ, Nelson RG, Kimmel PL, Rovin BH, Klein JB, Mauer M; CKD Biomarkers Consortium.

Am J Physiol Renal Physiol. 2018 Nov 1;315(5):F1484-F1492. doi: 10.1152/ajprenal.00183.2018. Epub 2018 Aug 22.

36.

Induction Therapy for Lupus Nephritis: the Highlights.

Ayoub I, Nelson J, Rovin BH.

Curr Rheumatol Rep. 2018 Aug 14;20(10):60. doi: 10.1007/s11926-018-0766-9. Review.

PMID:
30109511
37.

Peripheral Blood B Cell Depletion after Rituximab and Complete Response in Lupus Nephritis.

Gomez Mendez LM, Cascino MD, Garg J, Katsumoto TR, Brakeman P, Dall'Era M, Looney RJ, Rovin B, Dragone L, Brunetta P.

Clin J Am Soc Nephrol. 2018 Oct 8;13(10):1502-1509. doi: 10.2215/CJN.01070118. Epub 2018 Aug 8. Erratum in: Clin J Am Soc Nephrol. 2019 Jan 7;14(1):111.

38.

A prospective observational cohort study highlights kidney biopsy findings of lupus nephritis patients in remission who flare following withdrawal of maintenance therapy.

De Rosa M, Azzato F, Toblli JE, De Rosa G, Fuentes F, Nagaraja HN, Nash R, Rovin BH.

Kidney Int. 2018 Oct;94(4):788-794. doi: 10.1016/j.kint.2018.05.021. Epub 2018 Jul 23.

PMID:
30045812
39.

Response to: 'Antinuclear antibody as entry criterion for classification of systemic lupus erythematosus: pitfalls and opportunities' by Bossuyt et al.

Pisetsky DS, Spencer DM, Lipsky PE, Rovin BH.

Ann Rheum Dis. 2019 Aug;78(8):e77. doi: 10.1136/annrheumdis-2018-213841. Epub 2018 Jun 23. No abstract available.

PMID:
29936440
40.

Immune gene expression in kidney biopsies of lupus nephritis patients at diagnosis and at renal flare.

Mejia-Vilet JM, Parikh SV, Song H, Fadda P, Shapiro JP, Ayoub I, Yu L, Zhang J, Uribe-Uribe N, Rovin BH.

Nephrol Dial Transplant. 2019 Jul 1;34(7):1197-1206. doi: 10.1093/ndt/gfy125.

PMID:
29800348
41.

Response to: 'Pitfalls of antinuclear antibody detection in systemic lupus erythematosus: the positive experience of a national multi-center study' by Pregnalato et al.

Pisetsky DS, Spencer DM, Lipsky PE, Rovin BH.

Ann Rheum Dis. 2019 Jun;78(6):e51. doi: 10.1136/annrheumdis-2018-213582. Epub 2018 May 5. No abstract available.

PMID:
29730639
42.

Response to: 'Variation in antinuclear antibody detection by automated indirect immunofluorescence analysis' by van Hoovels et al.

Pisetsky DS, Spencer DM, Lipsky PE, Rovin BH.

Ann Rheum Dis. 2019 Jun;78(6):e49. doi: 10.1136/annrheumdis-2018-213558. Epub 2018 May 5. No abstract available.

PMID:
29730638
43.

Response to: 'Unending story of the indirect immunofluorescence assay on HEp-2 cells: old problems and new solutions?' by Meroni et al.

Pisetsky DS, Spencer DM, Lipsky PE, Rovin BH.

Ann Rheum Dis. 2019 Jun;78(6):e47. doi: 10.1136/annrheumdis-2018-213537. Epub 2018 Apr 28. No abstract available.

PMID:
29705742
44.

Lupus community panel proposals for optimising clinical trials: 2018.

Merrill JT, Manzi S, Aranow C, Askanase A, Bruce I, Chakravarty E, Chong B, Costenbader K, Dall'Era M, Ginzler E, Hanrahan L, Kalunian K, Merola J, Raymond S, Rovin B, Saxena A, Werth VP.

Lupus Sci Med. 2018 Mar 23;5(1):e000258. doi: 10.1136/lupus-2018-000258. eCollection 2018. Review. Erratum in: Lupus Sci Med. 2018 Jun 11;5(1):e000258corr1.

45.

Response to: 'Lack of standardization of ANA and implications for drug development and precision medicine' by Mahler.

Pisetsky DS, Spencer DM, Lipsky PE, Rovin BH.

Ann Rheum Dis. 2019 May;78(5):e34. doi: 10.1136/annrheumdis-2018-213399. Epub 2018 Mar 28. No abstract available.

PMID:
29592916
46.

Screening for cognitive impairment in SLE using the Self-Administered Gerocognitive Exam.

Meara A, Davidson N, Steigelman H, Zhao S, Brock G, Jarjour WN, Rovin BH, Madhoun H, Parikh S, Hebert L, Ayoub I, Ardoin SP.

Lupus. 2018 Jul;27(8):1363-1367. doi: 10.1177/0961203318759429. Epub 2018 Feb 21.

PMID:
29466913
47.

Assay variation in the detection of antinuclear antibodies in the sera of patients with established SLE.

Pisetsky DS, Spencer DM, Lipsky PE, Rovin BH.

Ann Rheum Dis. 2018 Jun;77(6):911-913. doi: 10.1136/annrheumdis-2017-212599. Epub 2018 Feb 9.

PMID:
29440000
48.

Acute kidney injury aggravated by treatment initiation with apixaban: Another twist of anticoagulant-related nephropathy.

Brodsky SV, Mhaskar NS, Thiruveedi S, Dhingra R, Reuben SC, Calomeni E, Ivanov I, Satoskar A, Hemminger J, Nadasdy G, Hebert L, Rovin B, Nadasdy T.

Kidney Res Clin Pract. 2017 Dec;36(4):387-392. doi: 10.23876/j.krcp.2017.36.4.387. Epub 2017 Dec 31.

49.

Safety and Efficacy of Combination ACTHar Gel and Tacrolimus in Treatment-Resistant Focal Segmental Glomerulosclerosis and Membranous Glomerulopathy.

Tumlin J, Galphin C, Santos R, Rovin B.

Kidney Int Rep. 2017 Jun 6;2(5):924-932. doi: 10.1016/j.ekir.2017.05.015. eCollection 2017 Sep.

50.

Abatacept efficacy in steroid-resistant minimal-change disease revealed by the speed of proteinuria reduction after the start of abatacept
.

Dado D, Parikh S, Ayoub I, Rovin B, Nadasdy T, Hebert L.

Clin Nephrol. 2018 May;89(5):376-380. doi: 10.5414/CN109290.

PMID:
29249233

Supplemental Content

Support Center